Arbutus Biopharma (ABUS) Tops Q1 EPS by 91c

Arbutus Biopharma (NASDAQ: ABUS) reported Q1 EPS of $0.87, $0.91 better than the analyst estimate of ($0.04). Revenue for the quarter came in at $179.23 million versus the consensus estimate of $400 thousand.

For earnings history and earnings-related data on Arbutus Biopharma (ABUS) click here.

You May Also Be Interested In

• Activist investors push Seer, Inc. to disclose go-private timeline
• Popular stocks with increasing option volume: SPCX MU SMCI INTC AMZN NFLX HTZ MSTR NBIS PLTR SNDK CRWV ORCL CSCO
• Active options: NVDA TSLA SPCX MU SMCI INTC AAPL IREN AMZN